Rocatinlimab achieved a 32.8% EASI-75 response at week 24, but fell short of market leader Dupixent’s results. Uplizna improved MG-ADL and QMG scores significantly, offering potential as a treatment ...
Breakthroughs, discoveries, and DIY tips sent every weekday. Terms of Service and Privacy Policy. The placebo effect can have a significant influence on treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback